



# Test Definition: FGAGM

Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies

## Overview

### Method Name

Semi-Quantitative Enzyme-Linked Immunosorbent Assay

### NY State Available

Yes

## Specimen

### Specimen Type

Serum SST

### Specimen Required

#### Collection Container/Tube:

**Preferred:** Serum gel

**Acceptable:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 0.5 mL Serum

#### Collection Instructions:

1. Within 2 hours of collection, centrifuge and aliquot 1 mL of serum into a plastic vial.
2. Send refrigerated.

### Specimen Minimum Volume

Serum: 0.1 mL

### Reject Due To

Gross hemolysis	Reject
Gross lipemia	Reject
Gross icterus	Reject
Contaminated specimens	Reject
Spinal fluid or other body fluids	Reject
Heat-inactivated specimens	Reject

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum SST	Refrigerated (preferred)	14 days	
	Frozen	365 days	

**Clinical & Interpretive****Clinical Information**Refer to <https://ltd.aruplab.com/>**Reference Values**

Negative: &lt; or =29 IV

Equivocal: 30-50 IV

Positive: 51-100

Strong Positive: &gt; or =101 IV

**Interpretation**

Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1) and the neutral glycolipid, asialo-GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS), particularly acute motor axonal neuropathy, while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80 percent of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

**Performance****PDF Report**

No

**Day(s) Performed**

Monday, Wednesday, Friday

**Report Available**

1 to 8 days

**Performing Laboratory Location**

ARUP Laboratories

---

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

**CPT Code Information**

83516 x 6

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
FGAGM	Ganglioside Antibodies, IgG-IgM	82455-7

Result ID	Test Result Name	Result LOINC® Value
Z4245	Asialo-GM1 Antibodies, IgG-IgM	88723-2
Z4246	GM1 Antibodies, IgG-IgM	31500-2
Z4247	GM2 Antibodies, IgG-IgM	88731-5
Z4248	GD1a Antibodies, IgG-IgM	88724-0
Z4249	GD1b Antibodies, IgG-IgM	88730-7
Z4250	GQ1b Antibodies, IgG-IgM	88729-9